Cartesian Therapeutics, Inc. (RNAC) shareholders
Close on Nov 12, 2026Market cap $192.42MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Timothy A. Springer | 9,555,394 | 36.90% | 13D (active) amendment | Jan 13, 2025 |
| Murat Kalayoglu Joint filing with Seven One Eight Three Four Irrevocable Trust (18.10%), Elizabeth Hoge (18.10%) and 1 more | 5,833,971 | 19.90% | 13D (active) amendment | Mar 31, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (9.40%) | 2,423,213 | 9.40% | 13G (passive) amendment | Dec 31, 2024 |
| Squarepoint (DIFC) Ltd Joint filing with Squarepoint Ops LLC (8.30%), Squarepoint Capital LLP (8.30%) and 2 more | 2,209,601 | 8.30% | 13G (passive) | Mar 9, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RNAC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Squarepoint Ops LLC | 2,254,619 | 7.45% | $23.49M | +16,133 | 0.03% |
| BlackRock, Inc. | 819,239 | 2.71% | $8.54M | +220,131 | 0.00% |
| 683 Capital Management, LLC | 650,000 | 2.15% | $6.77M | +320,000 | 0.33% |
| Vanguard Capital Management LLC | 555,823 | 1.84% | $5.79M | +148,226 | 0.00% |
| FMR LLC | 368,429 | 1.22% | $3.84M | −431,314 | 0.00% |
| Geode Capital Management, LLC | 356,525 | 1.18% | $3.72M | +92,831 | 0.00% |
| Aqr Capital Management LLC | 356,456 | 1.18% | $3.71M | +272,436 | 0.00% |
| Millennium Management LLC | 309,887 | 1.02% | $3.23M | +25,570 | 0.00% |
| Two Sigma Investments, LP | 296,293 | 0.98% | $3.09M | +128,980 | 0.00% |
| State Street Corp | 249,212 | 0.82% | $2.60M | +48,875 | 0.00% |
| Marshall Wace, Llp | 232,919 | 0.77% | $2.43M | −18,196 | 0.00% |
| UBS Group AG | 208,647 | 0.69% | $2.17M | +71,807 | 0.00% |
| Jupiter Topco LLC | 200,905 | 0.66% | $2.09M | New | 0.00% |
| Ironwood Investment Management LLC | 170,087 | 0.56% | $0 | – | 0.00% |
| Privium Fund Management B.V. | 151,675 | 0.50% | $1.58M | −27,439 | 0.29% |
| Northern Trust Corp | 105,698 | 0.35% | $1.10M | +13,706 | 0.00% |
| ADAR1 Capital Management, LLC | 98,877 | 0.33% | $1.03M | New | 0.05% |
| Vanguard Fiduciary Trust Co | 91,854 | 0.30% | $957.12K | +21,558 | 0.00% |
| Vanguard Portfolio Management LLC | 87,317 | 0.29% | $909.84K | +26,734 | 0.00% |
| Diadema Partners LP | 87,057 | 0.29% | $907.13K | New | 0.11% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 96 | 9M | 29.3% | 25 / 44 | 12 / 12 | 3M | 1M |
| Q1 2026 | 84 | 7M | 24.2% | 27 / 29 | 15 / 12 | 4M | 1M |
| Q4 2025 | 70 | 5M | 17.7% | 16 / 22 | 18 / 15 | 1M | 2M |
| Q3 2025 | 69 | 6M | 20.4% | 6 / 22 | 22 / 4 | 0M | 1M |
| Q2 2025 | 67 | 7M | 21.8% | 8 / 22 | 21 / 14 | 0M | 3M |
| Q1 2025 | 73 | 9M | 30.7% | 13 / 22 | 20 / 7 | 0M | 0M |
| Q4 2024 | 69 | 9M | 31.0% | 15 / 30 | 10 / 10 | 1M | 1M |
| Q3 2024 | 64 | 10M | 32.7% | 15 / 21 | 10 / 14 | 5M | 1M |
| Q2 2024 | 64 | 6M | 21.1% | 20 / 28 | 10 / 26 | 5M | 0M |
| Q1 2024 | 71 | 2M | 6.5% | 5 / 15 | 31 / 15 | 0M | 0M |
| Q4 2023 | 81 | 2M | 6.8% | 9 / 27 | 20 / 14 | 0M | 0M |
| Q3 2023 | 87 | 2M | 5.9% | 8 / 22 | 29 / 13 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
98 funds held RNAC in Q2 2026, 13% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RNAC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | 5,385,728 | 17.80% | $1.56M | 0.03% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 1,117,119 | 3.69% | $323.96K | 0.00% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 555,522 | 1.84% | $161.10K | 0.00% | May 31, 2026 |
| Vanguard Explorer Fund | 528,838 | 1.75% | $95.19K | 0.00% | Jul 31, 2026 |
| Small Company Growth Portfolio | 414,811 | 1.37% | $74.67K | 0.00% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 376,309 | 1.24% | $3.92M | 0.00% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 366,554 | 1.21% | $2.76M | 0.05% | May 31, 2026 |
| iShares Russell 2000 ETF | 338,605 | 1.12% | $3.53M | 0.00% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 265,512 | 0.88% | $613.12K | 0.01% | Jul 31, 2026 |
| WisdomTree U.S. SmallCap Fund | 242,132 | 0.80% | $33.03K | 0.00% | Jun 30, 2026 |
| Janus Henderson Small Cap Growth Alpha ETF | 195,163 | 0.65% | $1.52M | 0.42% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 188,029 | 0.62% | $54.53K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 169,730 | 0.56% | $1.77M | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 145,588 | 0.48% | $42.22K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 144,043 | 0.48% | $1.12M | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Carsten Brunn | President and CEO, Director | 323,530 | 1.07% | Jan 8, 2026 |
| Milos Miljkovic | Chief Medical Officer | 58,820 | 0.19% | Jan 8, 2026 |
| Blaine Davis | Chief Financial Officer | 121,220 | 0.40% | Jan 8, 2026 |
| Emily English | Chief Operations Officer | 94,226 | 0.31% | Jan 6, 2026 |
| June Ann Seymour | Chief Accounting Officer | 6,500 | 0.02% | Jan 6, 2026 |
| Christopher M. Jewell | Chief Scientific Officer | 62,490 | 0.21% | Jan 13, 2025 |
| Metin Kurtoglu | Chief Technology Officer | 62,258 | 0.21% | Jan 7, 2025 |
| Michael Singer | Director | 544,381 | 1.80% | Mar 13, 2026 |
| Timothy C. Barabe | Director | 56,966 | 0.19% | Jan 6, 2026 |
| Patrick J. Zenner | Director | 12,974 | 0.04% | Jan 6, 2026 |
| Nishan M. DeSilva | Director | 11,366 | 0.04% | Jan 6, 2026 |
| Timothy A. Springer | Director, 10% owner | 9,633,493 | 31.84% | Jan 6, 2026 |
| Kemal Malik | Director | 11,133 | 0.04% | Jan 6, 2026 |
| Adrian Ion Bot | Director | 5,800 | 0.02% | Dec 18, 2025 |
| Carrie Smith Cox | Director | 15,629 | 0.05% | Jan 6, 2025 |
| Elizabeth Hoge | 10% owner | 5,820,260 | 19.24% | Apr 6, 2026 |
| One Eight Three Four Irrevocable Trust Seven | 10% owner | 5,061,637 | 16.73% | Apr 6, 2026 |
| Murat Kalayoglu | 10% owner | 5,820,260 | 19.24% | Apr 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Murat Kalayoglu 10% owner | Apr 2, 2026 | Option exercise | +758,001 | – | – | 5,313,261 |
| Elizabeth Hoge 10% owner | Apr 2, 2026 | Option exercise | +758,001 | – | – | 5,313,261 |
| Michael Singer Director | Mar 13, 2026 | Gift | −6,555 | – | – | 49,578 |
| Carsten Brunn President and CEO, Director | Jan 6, 2026 | Sale | −23,766 | $6.82 | $162.08K | 323,530 |
| Milos Miljkovic Chief Medical Officer | Jan 6, 2026 | Sale | −3,573 | $6.82 | $24.37K | 58,820 |
| Blaine Davis Chief Financial Officer | Jan 6, 2026 | Sale | −10,591 | $6.82 | $72.23K | 121,220 |
| June Ann Seymour Chief Accounting Officer | Jan 2, 2026 | Award | +6,500 | – | – | 6,500 |
| Murat Kalayoglu Director, 10% owner | Jan 2, 2026 | Award | +2,600 | – | – | 511,577 |
| Carsten Brunn President and CEO, Director | Jan 2, 2026 | Award | +143,200 | – | – | 347,296 |
| Kemal Malik Director | Jan 2, 2026 | Award | +2,600 | – | – | 11,133 |
| Nishan M. DeSilva Director | Jan 2, 2026 | Award | +2,600 | – | – | 11,366 |
| Timothy A. Springer Director, 10% owner | Jan 2, 2026 | Award | +2,600 | – | – | 8,646,285 |
| Blaine Davis Chief Financial Officer | Jan 2, 2026 | Award | +37,000 | – | – | 131,811 |
| Timothy C. Barabe Director | Jan 2, 2026 | Award | +2,600 | – | – | 56,966 |
| Emily English Chief Operations Officer | Jan 2, 2026 | Award | +24,000 | – | – | 94,226 |
| Milos Miljkovic Chief Medical Officer | Jan 2, 2026 | Award | +27,000 | – | – | 62,393 |
| Patrick J. Zenner Director | Jan 2, 2026 | Award | +2,600 | – | – | 12,974 |
| Michael Singer Director | Jan 2, 2026 | Award | +2,600 | – | – | 56,133 |
| Emily English Chief Operations Officer | Dec 30, 2025 | Option exercise | +7,500 | $3.30 | $24.75K | 70,226 |
| Adrian Ion Bot Director | Dec 16, 2025 | Award | +5,800 | – | – | 5,800 |
| Timothy C. Barabe Director | Dec 4, 2025 | Buy | +30,000 | $6.86 | $205.80K | 54,366 |
| Emily English Chief Operations Officer | Nov 28, 2025 | Option exercise | +7,500 | $3.30 | $24.75K | 62,726 |
| Michael Singer Director | Nov 18, 2025 | Gift | −20,000 | – | – | 53,533 |
| Emily English Chief Operations Officer | May 12, 2025 | Option exercise | +7,500 | $3.30 | $24.75K | 55,226 |
| Emily English Chief Operations Officer | Apr 15, 2025 | Option exercise | +7,500 | $3.30 | $24.75K | 47,726 |
| Timothy A. Springer Director, 10% owner | Apr 11, 2025 | Buy | +36,338 | $10.77 | $391.36K | 656,513 |
| Timothy A. Springer Director, 10% owner | Apr 11, 2025 | Buy | +6,412 | $10.77 | $69.06K | 8,643,685 |
| Timothy A. Springer Director, 10% owner | Apr 10, 2025 | Buy | +3,451 | $10.92 | $37.68K | 620,175 |
| Timothy A. Springer Director, 10% owner | Apr 10, 2025 | Buy | +609 | $10.92 | $6.65K | 8,637,273 |
| Timothy A. Springer Director, 10% owner | Apr 10, 2025 | Buy | +7,966 | $10.43 | $83.09K | 8,636,664 |
| Timothy A. Springer Director, 10% owner | Apr 10, 2025 | Buy | +45,144 | $10.43 | $470.85K | 616,724 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +7,342 | $9.43 | $69.24K | 8,628,667 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +41,604 | $9.43 | $392.33K | 571,402 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +178 | $9.95 | $1.77K | 571,580 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +31 | $9.95 | $308 | 8,628,698 |
| Timothy A. Springer Director, 10% owner | Mar 20, 2025 | Buy | +54,889 | $15.59 | $855.72K | 8,621,325 |
| Timothy A. Springer Director, 10% owner | Mar 19, 2025 | Buy | +20,234 | $14.97 | $302.90K | 8,566,436 |
| Timothy A. Springer Director, 10% owner | Mar 18, 2025 | Buy | +14,740 | $14.42 | $212.55K | 8,546,202 |
| Timothy A. Springer Director, 10% owner | Jan 14, 2025 | Buy | +4,022 | $18.00 | $72.40K | 8,531,462 |
| Timothy A. Springer Director, 10% owner | Jan 13, 2025 | Buy | +8,983 | $17.78 | $159.72K | 8,527,440 |
| Timothy A. Springer Director, 10% owner | Jan 13, 2025 | Buy | +7,962 | $16.86 | $134.24K | 8,518,457 |
| Christopher M. Jewell Chief Scientific Officer | Jan 10, 2025 | Option exercise | +9,000 | $3.23 | $29.07K | 62,490 |
| Metin Kurtoglu Chief Technology Officer | Jan 6, 2025 | Sale | −2,458 | $16.83 | $41.37K | 62,258 |
| Emily English Chief Operations Officer | Jan 6, 2025 | Sale | −906 | $16.83 | $15.25K | 40,226 |
| Milos Miljkovic Chief Medical Officer | Jan 6, 2025 | Sale | −948 | $16.83 | $15.95K | 35,393 |
| Blaine Davis Chief Financial Officer | Jan 6, 2025 | Sale | −4,028 | $16.83 | $67.79K | 94,811 |
| Christopher M. Jewell Chief Scientific Officer | Jan 6, 2025 | Sale | −1,286 | $16.83 | $21.64K | 53,490 |
| Carsten Brunn President and CEO, Director | Jan 6, 2025 | Sale | −8,708 | $16.83 | $146.56K | 204,096 |
| Metin Kurtoglu Chief Technology Officer | Jan 3, 2025 | Sale | −2,417 | $16.72 | $40.41K | 64,716 |
| Emily English Chief Operations Officer | Jan 3, 2025 | Sale | −891 | $16.72 | $14.90K | 41,132 |
| Milos Miljkovic Chief Medical Officer | Jan 3, 2025 | Sale | −932 | $16.72 | $15.58K | 36,341 |
| Blaine Davis Chief Financial Officer | Jan 3, 2025 | Sale | −3,961 | $16.72 | $66.23K | 98,839 |
| Christopher M. Jewell Chief Scientific Officer | Jan 3, 2025 | Sale | −1,264 | $16.72 | $21.13K | 54,776 |
| Carsten Brunn President and CEO, Director | Jan 3, 2025 | Sale | −8,563 | $16.72 | $143.17K | 212,804 |
| Christopher M. Jewell Chief Scientific Officer | Jan 2, 2025 | Award | +16,100 | – | – | 56,040 |
| Murat Kalayoglu Director, 10% owner | Jan 2, 2025 | Award | +2,600 | – | – | 508,977 |
| Carsten Brunn President and CEO, Director | Jan 2, 2025 | Award | +57,500 | – | – | 221,367 |
| Carrie Smith Cox Director | Jan 2, 2025 | Award | +2,600 | – | – | 15,629 |
| Milos Miljkovic Chief Medical Officer | Jan 2, 2025 | Award | +19,000 | – | – | 37,273 |
| Metin Kurtoglu Chief Technology Officer | Jan 2, 2025 | Award | +16,100 | – | – | 67,133 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cartesian Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,411 shares on Sep 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Milos Miljkovic Former Affiliate | Jun 9, 2026 | 35,038 | $232.73K | Jun 9, 2026 | Exercise of Options Under a Registered Plan |
| Milos Miljkovic Former Affiliate | Jun 2, 2026 | 3,924 | $25.15K | Jun 2, 2026 | Restricted stock vesting under a registered plan |
| Christopher M. Jewell Former Affiliate | Jan 13, 2026 | 9,000 | $68.94K | Jan 13, 2026 | Exercise of options under a registered plan |
| Christopher M. Jewell Former Affiliate | Jan 9, 2026 | 1,510 | $12.11K | Jan 9, 2026 | Restricted stock vesting under a registered plan |
| Christopher M. Jewell Former Affiliate | Nov 19, 2025 | 26,935 | $192.59K | Nov 19, 2025 | Previously Exercised Options |
| Metin Kurtoglu Officer | Dec 10, 2024 | 2,901 | $70.64K | Dec 10, 2024 | Exercise of options under a registered plan |
| Metin Kurtoglu Officer | Dec 9, 2024 | 10,763 | $274.49K | Dec 9, 2024 | Exercise of options under a registered plan |
| Metin Kurtoglu Officer | Nov 21, 2024 | 32,789 | $546.56K | Nov 21, 2024 | Exercise of options under a registered plan |
| Metin Kurtoglu Officer | Nov 20, 2024 | 5,700 | $98.57K | Nov 20, 2024 | Exercise of options under a registered plan |
| Metin Kurtoglu Officer | Nov 19, 2024 | 200 | $3.90K | Nov 19, 2024 | Exercise of options under a registered plan |
| Metin Kurtoglu Officer | Nov 18, 2024 | 34,400 | $632.64K | Nov 18, 2024 | Exercise of options under a registered plan |
| Christopher M. Jewell Officer | Nov 15, 2024 | 16,065 | $274.09K | Nov 15, 2024 | Exercise of options under a registered plan |
| Milos Miljkovic Officer | Nov 15, 2024 | 20,000 | $342.89K | Nov 15, 2024 | Exercise of options under a registered plan |
| Metin Kurtoglu Officer | Nov 15, 2024 | 22,068 | $379.50K | Nov 15, 2024 | Exercise of options under a registered plan |
| Christopher M. Jewell Officer | Nov 14, 2024 | 36,050 | $600.95K | Nov 14, 2024 | Exercise of options under a registered plan |
See a number that looks wrong?